APO Research
Talk to an analyst

APO RESEARCH · REPORT

Calcitonin Gene Related Peptide Type 1

Compare research editions
View pricing & licenses

Selected research

Industry Research

Calcitonin Gene Related Peptide Type 1 Industry Research Report 2026

22 December 2025118 pages

Choose your research edition.

Industry ResearchCalcitonin Gene Related Peptide Type 1 Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Calcitonin Gene Related Peptide Type 1 Industry Growth and Trends Forecast to 203292 pages · $3,450 USDMarket StructureGlobal Calcitonin Gene Related Peptide Type 1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Calcitonin Gene Related Peptide Type 1 Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Calcitonin Gene Related Peptide Type 1 Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Calcitonin Gene Related Peptide Type 1 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Calcitonin Gene Related Peptide Type 1 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Calcitonin Gene Related Peptide Type 1 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Calcitonin Gene Related Peptide Type 1 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Calcitonin Gene Related Peptide Type 1 include Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, Amgen Inc, Vertex Pharmaceuticals Inc, Merck & Co Inc, Fortress Biotech Inc, Biohaven Pharmaceutical Holding Company Ltd and Allergan Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Calcitonin Gene Related Peptide Type 1 market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Calcitonin Gene Related Peptide Type 1 Market by Company

Teva Pharmaceutical Industries Ltd

Eli Lilly and Company

Amgen Inc

Vertex Pharmaceuticals Inc

Merck & Co Inc

Fortress Biotech Inc

Biohaven Pharmaceutical Holding Company Ltd

Allergan Plc

Calcitonin Gene Related Peptide Type 1 Segment by Type

Erenumab

CGRP

AGN-241689

AFAP-3

Others

Calcitonin Gene Related Peptide Type 1 Segment by Application

Dental Pain

Cardiovascular

Metabolic Disorders

Others

Calcitonin Gene Related Peptide Type 1 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Calcitonin Gene Related Peptide Type 1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Calcitonin Gene Related Peptide Type 1 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Calcitonin Gene Related Peptide Type 1.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Calcitonin Gene Related Peptide Type 1 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Calcitonin Gene Related Peptide Type 1 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Calcitonin Gene Related Peptide Type 1 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Calcitonin Gene Related Peptide Type 1 Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Calcitonin Gene Related Peptide Type 1 Sales (k units) of Manufacturers (2021-2026) Table 7. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Manufacturers (2021-2026) Table 8. Global Calcitonin Gene Related Peptide Type 1 Revenue of Manufacturers (2021-2026) Table 9. Global Calcitonin Gene Related Peptide Type 1 Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Calcitonin Gene Related Peptide Type 1 Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Calcitonin Gene Related Peptide Type 1 Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Calcitonin Gene Related Peptide Type 1, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Calcitonin Gene Related Peptide Type 1, Product Type & Application Table 14. Global Calcitonin Gene Related Peptide Type 1 Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Calcitonin Gene Related Peptide Type 1 by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Teva Pharmaceutical Industries Ltd Company Information Table 19. Teva Pharmaceutical Industries Ltd Business Overview Table 20. Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide Type 1 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 22. Teva Pharmaceutical Industries Ltd Recent Developments Table 23. Eli Lilly and Company Company Information Table 24. Eli Lilly and Company Business Overview Table 25. Eli Lilly and Company Calcitonin Gene Related Peptide Type 1 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Eli Lilly and Company Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 27. Eli Lilly and Company Recent Developments Table 28. Amgen Inc Company Information Table 29. Amgen Inc Business Overview Table 30. Amgen Inc Calcitonin Gene Related Peptide Type 1 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Amgen Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 32. Amgen Inc Recent Developments Table 33. Vertex Pharmaceuticals Inc Company Information Table 34. Vertex Pharmaceuticals Inc Business Overview Table 35. Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 37. Vertex Pharmaceuticals Inc Recent Developments Table 38. Merck & Co Inc Company Information Table 39. Merck & Co Inc Business Overview Table 40. Merck & Co Inc Calcitonin Gene Related Peptide Type 1 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Merck & Co Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 42. Merck & Co Inc Recent Developments Table 43. Fortress Biotech Inc Company Information Table 44. Fortress Biotech Inc Business Overview Table 45. Fortress Biotech Inc Calcitonin Gene Related Peptide Type 1 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Fortress Biotech Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 47. Fortress Biotech Inc Recent Developments Table 48. Biohaven Pharmaceutical Holding Company Ltd Company Information Table 49. Biohaven Pharmaceutical Holding Company Ltd Business Overview Table 50. Biohaven Pharmaceutical Holding Company Ltd Calcitonin Gene Related Peptide Type 1 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Biohaven Pharmaceutical Holding Company Ltd Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 52. Biohaven Pharmaceutical Holding Company Ltd Recent Developments Table 53. Allergan Plc Company Information Table 54. Allergan Plc Business Overview Table 55. Allergan Plc Calcitonin Gene Related Peptide Type 1 Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Allergan Plc Calcitonin Gene Related Peptide Type 1 Product Portfolio Table 57. Allergan Plc Recent Developments Table 58. Global Calcitonin Gene Related Peptide Type 1 Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 59. Global Calcitonin Gene Related Peptide Type 1 Sales by Region (2021-2026) & (k units) Table 60. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Region (2021-2026) Table 61. Global Calcitonin Gene Related Peptide Type 1 Sales by Region (2027-2032) & (k units) Table 62. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Region (2027-2032) Table 63. Global Calcitonin Gene Related Peptide Type 1 Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Region (2021-2026) Table 65. Global Calcitonin Gene Related Peptide Type 1 Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Region (2027-2032) Table 67. North America Calcitonin Gene Related Peptide Type 1 Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 68. North America Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2026) & (k units) Table 69. North America Calcitonin Gene Related Peptide Type 1 Sales by Country (2027-2032) & (k units) Table 70. North America Calcitonin Gene Related Peptide Type 1 Revenue by Country (2021-2026) & (US$ Million) Table 71. North America Calcitonin Gene Related Peptide Type 1 Revenue by Country (2027-2032) & (US$ Million) Table 72. Europe Calcitonin Gene Related Peptide Type 1 Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 73. Europe Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2026) & (k units) Table 74. Europe Calcitonin Gene Related Peptide Type 1 Sales by Country (2027-2032) & (k units) Table 75. Europe Calcitonin Gene Related Peptide Type 1 Revenue by Country (2021-2026) & (US$ Million) Table 76. Europe Calcitonin Gene Related Peptide Type 1 Revenue by Country (2027-2032) & (US$ Million) Table 77. Asia Pacific Calcitonin Gene Related Peptide Type 1 Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 78. Asia Pacific Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2026) & (k units) Table 79. Asia Pacific Calcitonin Gene Related Peptide Type 1 Sales by Country (2027-2032) & (k units) Table 80. Asia Pacific Calcitonin Gene Related Peptide Type 1 Revenue by Country (2021-2026) & (US$ Million) Table 81. Asia Pacific Calcitonin Gene Related Peptide Type 1 Revenue by Country (2027-2032) & (US$ Million) Table 82. South America Calcitonin Gene Related Peptide Type 1 Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 83. South America Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2026) & (k units) Table 84. South America Calcitonin Gene Related Peptide Type 1 Sales by Country (2027-2032) & (k units) Table 85. South America Calcitonin Gene Related Peptide Type 1 Revenue by Country (2021-2026) & (US$ Million) Table 86. South America Calcitonin Gene Related Peptide Type 1 Revenue by Country (2027-2032) & (US$ Million) Table 87. Middle East and Africa Calcitonin Gene Related Peptide Type 1 Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. Middle East and Africa Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2026) & (k units) Table 89. Middle East and Africa Calcitonin Gene Related Peptide Type 1 Sales by Country (2027-2032) & (k units) Table 90. Middle East and Africa Calcitonin Gene Related Peptide Type 1 Revenue by Country (2021-2026) & (US$ Million) Table 91. Middle East and Africa Calcitonin Gene Related Peptide Type 1 Revenue by Country (2027-2032) & (US$ Million) Table 92. Global Calcitonin Gene Related Peptide Type 1 Sales by Type (2021-2026) & (k units) Table 93. Global Calcitonin Gene Related Peptide Type 1 Sales by Type (2027-2032) & (k units) Table 94. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Type (2021-2026) Table 95. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Type (2027-2032) Table 96. Global Calcitonin Gene Related Peptide Type 1 Revenue by Type (2021-2026) & (US$ Million) Table 97. Global Calcitonin Gene Related Peptide Type 1 Revenue by Type (2027-2032) & (US$ Million) Table 98. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Type (2021-2026) Table 99. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Type (2027-2032) Table 100. Global Calcitonin Gene Related Peptide Type 1 Price by Type (2021-2026) & (US$/unit) Table 101. Global Calcitonin Gene Related Peptide Type 1 Price by Type (2027-2032) & (US$/unit) Table 102. Global Calcitonin Gene Related Peptide Type 1 Sales by Application (2021-2026) & (k units) Table 103. Global Calcitonin Gene Related Peptide Type 1 Sales by Application (2027-2032) & (k units) Table 104. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Application (2021-2026) Table 105. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Application (2027-2032) Table 106. Global Calcitonin Gene Related Peptide Type 1 Revenue by Application (2021-2026) & (US$ Million) Table 107. Global Calcitonin Gene Related Peptide Type 1 Revenue by Application (2027-2032) & (US$ Million) Table 108. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Application (2021-2026) Table 109. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Application (2027-2032) Table 110. Global Calcitonin Gene Related Peptide Type 1 Price by Application (2021-2026) & (US$/unit) Table 111. Global Calcitonin Gene Related Peptide Type 1 Price by Application (2027-2032) & (US$/unit) Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Calcitonin Gene Related Peptide Type 1 Distributors List Table 115. Calcitonin Gene Related Peptide Type 1 Customers List Table 116. Calcitonin Gene Related Peptide Type 1 Industry Trends Table 117. Calcitonin Gene Related Peptide Type 1 Industry Drivers Table 118. Calcitonin Gene Related Peptide Type 1 Industry Restraints Table 119. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Calcitonin Gene Related Peptide Type 1 Product Image Figure 5. Global Calcitonin Gene Related Peptide Type 1 Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Calcitonin Gene Related Peptide Type 1 Market Size (2021-2032) & (US$ Million) Figure 7. Global Calcitonin Gene Related Peptide Type 1 Sales (2021-2032) & (k units) Figure 8. Global Calcitonin Gene Related Peptide Type 1 Average Price (US$/unit) & (2021-2032) Figure 9. Erenumab Product Image Figure 10. CGRP Product Image Figure 11. AGN-241689 Product Image Figure 12. AFAP-3 Product Image Figure 13. Others Product Image Figure 14. Dental Pain Product Image Figure 15. Cardiovascular Product Image Figure 16. Metabolic Disorders Product Image Figure 17. Others Product Image Figure 18. Global Calcitonin Gene Related Peptide Type 1 Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Calcitonin Gene Related Peptide Type 1, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Calcitonin Gene Related Peptide Type 1 Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Calcitonin Gene Related Peptide Type 1 Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Calcitonin Gene Related Peptide Type 1 Sales by Region in 2025 Figure 24. Global Calcitonin Gene Related Peptide Type 1 Revenue by Region in 2025 Figure 25. North America Calcitonin Gene Related Peptide Type 1 Market Size by Country in 2025 Figure 26. North America Calcitonin Gene Related Peptide Type 1 Sales Market Share by Country (2021-2032) Figure 27. North America Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Country (2021-2032) Figure 28. United States Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Mexico Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Calcitonin Gene Related Peptide Type 1 Market Size by Country in 2025 Figure 32. Europe Calcitonin Gene Related Peptide Type 1 Sales Market Share by Country (2021-2032) Figure 33. Europe Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Country (2021-2032) Figure 34. Germany Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Russia Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Spain Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Netherlands Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Switzerland Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Sweden Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Poland Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Asia Pacific Calcitonin Gene Related Peptide Type 1 Market Size by Country in 2025 Figure 45. Asia Pacific Calcitonin Gene Related Peptide Type 1 Sales Market Share by Country (2021-2032) Figure 46. Asia Pacific Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Country (2021-2032) Figure 47. China Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Japan Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South Korea Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. India Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Australia Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Taiwan Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. South America Calcitonin Gene Related Peptide Type 1 Market Size by Country in 2025 Figure 56. South America Calcitonin Gene Related Peptide Type 1 Sales Market Share by Country (2021-2032) Figure 57. South America Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Country (2021-2032) Figure 58. Brazil Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Argentina Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Chile Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Middle East and Africa Calcitonin Gene Related Peptide Type 1 Market Size by Country in 2025 Figure 62. Middle East and Africa Calcitonin Gene Related Peptide Type 1 Sales Market Share by Country (2021-2032) Figure 63. Middle East and Africa Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Country (2021-2032) Figure 64. Egypt Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. South Africa Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Israel Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Türkiye Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. GCC Countries Calcitonin Gene Related Peptide Type 1 Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Type (2021-2032) Figure 70. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Type (2021-2032) Figure 71. Global Calcitonin Gene Related Peptide Type 1 Price (US$/unit) by Type (2021-2032) Figure 72. Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Application (2021-2032) Figure 73. Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Application (2021-2032) Figure 74. Global Calcitonin Gene Related Peptide Type 1 Price (US$/unit) by Application (2021-2032) Figure 75. Calcitonin Gene Related Peptide Type 1 Value Chain Figure 76. Calcitonin Gene Related Peptide Type 1 Production Mode & Process Figure 77. Direct Comparison with Distribution Share Figure 78. Distributors Profiles Figure 79. Calcitonin Gene Related Peptide Type 1 Industry Opportunities and Challenges

Scope & coverage.

Types
  • Erenumab
  • CGRP
  • AGN-241689
  • AFAP-3
  • Others
Applications
  • Dental Pain
  • Cardiovascular
  • Metabolic Disorders
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Eli Lilly and Company
  • Amgen Inc
  • Vertex Pharmaceuticals Inc
  • Merck & Co Inc
  • Fortress Biotech Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Allergan Plc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Calcitonin Gene Related Peptide Type 1 Market Size (2021-2032)
  4. 2.2.2 Global Calcitonin Gene Related Peptide Type 1 Sales (2021-2032)
  5. 2.2.3 Global Calcitonin Gene Related Peptide Type 1 Market Average Price (2021-2032)
  6. 2.3 Calcitonin Gene Related Peptide Type 1 by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Erenumab
  9. 2.3.3 CGRP
  10. 2.3.4 AGN-241689
  11. 2.3.5 AFAP-3
  12. 2.3.6 Others
  13. 2.4 Calcitonin Gene Related Peptide Type 1 by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Dental Pain
  16. 2.4.3 Cardiovascular
  17. 2.4.4 Metabolic Disorders
  18. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Calcitonin Gene Related Peptide Type 1 Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Calcitonin Gene Related Peptide Type 1 Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Calcitonin Gene Related Peptide Type 1 Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Calcitonin Gene Related Peptide Type 1 Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Calcitonin Gene Related Peptide Type 1 Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Calcitonin Gene Related Peptide Type 1, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Calcitonin Gene Related Peptide Type 1, Product Type & Application
  8. 3.8 Global Manufacturers of Calcitonin Gene Related Peptide Type 1, Established Date
  9. 3.9 Global Calcitonin Gene Related Peptide Type 1 Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Teva Pharmaceutical Industries Ltd
  2. 4.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 4.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 4.1.3 Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide Type 1 Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Teva Pharmaceutical Industries Ltd Calcitonin Gene Related Peptide Type 1 Product Portfolio
  6. 4.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 4.2 Eli Lilly and Company
  8. 4.2.1 Eli Lilly and Company Company Information
  9. 4.2.2 Eli Lilly and Company Business Overview
  10. 4.2.3 Eli Lilly and Company Calcitonin Gene Related Peptide Type 1 Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Eli Lilly and Company Calcitonin Gene Related Peptide Type 1 Product Portfolio
  12. 4.2.5 Eli Lilly and Company Recent Developments
  13. 4.3 Amgen Inc
  14. 4.3.1 Amgen Inc Company Information
  15. 4.3.2 Amgen Inc Business Overview
  16. 4.3.3 Amgen Inc Calcitonin Gene Related Peptide Type 1 Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Amgen Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  18. 4.3.5 Amgen Inc Recent Developments
  19. 4.4 Vertex Pharmaceuticals Inc
  20. 4.4.1 Vertex Pharmaceuticals Inc Company Information
  21. 4.4.2 Vertex Pharmaceuticals Inc Business Overview
  22. 4.4.3 Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Vertex Pharmaceuticals Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  24. 4.4.5 Vertex Pharmaceuticals Inc Recent Developments
  25. 4.5 Merck & Co Inc
  26. 4.5.1 Merck & Co Inc Company Information
  27. 4.5.2 Merck & Co Inc Business Overview
  28. 4.5.3 Merck & Co Inc Calcitonin Gene Related Peptide Type 1 Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Merck & Co Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  30. 4.5.5 Merck & Co Inc Recent Developments
  31. 4.6 Fortress Biotech Inc
  32. 4.6.1 Fortress Biotech Inc Company Information
  33. 4.6.2 Fortress Biotech Inc Business Overview
  34. 4.6.3 Fortress Biotech Inc Calcitonin Gene Related Peptide Type 1 Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Fortress Biotech Inc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  36. 4.6.5 Fortress Biotech Inc Recent Developments
  37. 4.7 Biohaven Pharmaceutical Holding Company Ltd
  38. 4.7.1 Biohaven Pharmaceutical Holding Company Ltd Company Information
  39. 4.7.2 Biohaven Pharmaceutical Holding Company Ltd Business Overview
  40. 4.7.3 Biohaven Pharmaceutical Holding Company Ltd Calcitonin Gene Related Peptide Type 1 Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Biohaven Pharmaceutical Holding Company Ltd Calcitonin Gene Related Peptide Type 1 Product Portfolio
  42. 4.7.5 Biohaven Pharmaceutical Holding Company Ltd Recent Developments
  43. 4.8 Allergan Plc
  44. 4.8.1 Allergan Plc Company Information
  45. 4.8.2 Allergan Plc Business Overview
  46. 4.8.3 Allergan Plc Calcitonin Gene Related Peptide Type 1 Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Allergan Plc Calcitonin Gene Related Peptide Type 1 Product Portfolio
  48. 4.8.5 Allergan Plc Recent Developments
5 Global Calcitonin Gene Related Peptide Type 1 Market Scenario by Region
  1. 5.1 Global Calcitonin Gene Related Peptide Type 1 Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Calcitonin Gene Related Peptide Type 1 Sales by Region: 2021-2032
  3. 5.2.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Region: 2021-2026
  4. 5.2.2 Global Calcitonin Gene Related Peptide Type 1 Sales by Region: 2027-2032
  5. 5.3 Global Calcitonin Gene Related Peptide Type 1 Revenue by Region: 2021-2032
  6. 5.3.1 Global Calcitonin Gene Related Peptide Type 1 Revenue by Region: 2021-2026
  7. 5.3.2 Global Calcitonin Gene Related Peptide Type 1 Revenue by Region: 2027-2032
  8. 5.4 North America Calcitonin Gene Related Peptide Type 1 Market Facts & Figures by Country
  9. 5.4.1 North America Calcitonin Gene Related Peptide Type 1 Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2032)
  11. 5.4.3 North America Calcitonin Gene Related Peptide Type 1 Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Calcitonin Gene Related Peptide Type 1 Market Facts & Figures by Country
  16. 5.5.1 Europe Calcitonin Gene Related Peptide Type 1 Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2032)
  18. 5.5.3 Europe Calcitonin Gene Related Peptide Type 1 Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Calcitonin Gene Related Peptide Type 1 Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Calcitonin Gene Related Peptide Type 1 Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Calcitonin Gene Related Peptide Type 1 Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Calcitonin Gene Related Peptide Type 1 Market Facts & Figures by Country
  41. 5.7.1 South America Calcitonin Gene Related Peptide Type 1 Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2032)
  43. 5.7.3 South America Calcitonin Gene Related Peptide Type 1 Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Calcitonin Gene Related Peptide Type 1 Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Calcitonin Gene Related Peptide Type 1 Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Calcitonin Gene Related Peptide Type 1 Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Calcitonin Gene Related Peptide Type 1 Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Type (2021-2032)
  2. 6.1.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Type (2021-2032)
  4. 6.2 Global Calcitonin Gene Related Peptide Type 1 Revenue by Type (2021-2032)
  5. 6.2.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Calcitonin Gene Related Peptide Type 1 Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Application (2021-2032)
  2. 7.1.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Calcitonin Gene Related Peptide Type 1 Sales Market Share by Application (2021-2032)
  4. 7.2 Global Calcitonin Gene Related Peptide Type 1 Revenue by Application (2021-2032)
  5. 7.2.1 Global Calcitonin Gene Related Peptide Type 1 Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Calcitonin Gene Related Peptide Type 1 Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Calcitonin Gene Related Peptide Type 1 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Calcitonin Gene Related Peptide Type 1 Value Chain Analysis
  2. 8.1.1 Calcitonin Gene Related Peptide Type 1 Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Calcitonin Gene Related Peptide Type 1 Production Mode & Process
  5. 8.2 Calcitonin Gene Related Peptide Type 1 Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Calcitonin Gene Related Peptide Type 1 Distributors
  8. 8.2.3 Calcitonin Gene Related Peptide Type 1 Customers
9 Global Calcitonin Gene Related Peptide Type 1 Analyzing Market Dynamics
  1. 9.1 Calcitonin Gene Related Peptide Type 1 Industry Trends
  2. 9.2 Calcitonin Gene Related Peptide Type 1 Industry Drivers
  3. 9.3 Calcitonin Gene Related Peptide Type 1 Industry Opportunities and Challenges
  4. 9.4 Calcitonin Gene Related Peptide Type 1 Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst